Navigation Links
Bioenergy Introduces Corvalen M(R) as a Natural Treatment Option for Fibromyalgia Symptoms
Date:5/27/2010

MINNEAPOLIS, May 27 /PRNewswire/ -- Fibromyalgia affects as many as one in 50 Americans, 90 percent of whom are women. Yet, despite its nearly epidemic status, patients still often rely on pharmaceutical options solely for treatment. That's why Bioenergy Life Science, Inc. (www.bioenergy.com) has introduced Corvalen M®, a natural treatment option for fibromyalgia symptoms.  

Fibromyalgia is a syndrome mainly associated with widespread muscular pains and fatigue. The exact causes of fibromyalgia are unknown; however, patients with fibromyalgia have been shown to have an alteration in muscle adenine nucleotide metabolism, leading to depleted energy reserves (1).  As an essential compound in increasing muscular energy pools and reducing metabolic strain in affected muscles, Corvalen M® has been shown to be effective against fibromyalgia symptoms (2).

Corvalen M® comprises D-Ribose, a simple, 5-carbon monosaccharide, or pentose sugar. D-Ribose helps accelerate the formation of adenosine triphosphate (ATP), the primary energy source of all living cells, which can lead to subsequent tissue recovery for fibromyalgia patients.

"Having had Chronic Fatigue Syndrome and Fibromyalgia back in 1975, I know what patients are going through," says Dr. Jacob Teitelbaum, M.D, one of the primary researchers of this study and the medical director of the Fibromyalgia and Fatigue Centers, Inc. "The good news is these illnesses have become very treatable!"

Teitelbaum conducted a multi-center study, in which 53 health practitioners enrolled 257 patients who had been diagnosed with fibromyalgia and/or chronic fatigue syndrome. Each patient was given D-Ribose (Corvalen) at a dose of five grams per day for three weeks. All patients were measured for changes in energy, sleep, cognitive function, pain and overall well-being.

Teitelbaum noted improvement in the first week of treatment. After three weeks, results showed statistically significant improvements in all five parameters, More than half of the study's patients showed improvement in energy (61 percent), followed by a 37 percent increase in overall well-being.  

Bioenergy Life Science, Inc. focuses its core technology on D-Ribose®, the primary ingredient in the Corvalen Medical Food family of products, which include Corvalen®, Corvalen M® and Corvalen® Chewable Wafers. D-Ribose® is the only ribose to receive GRAS (generally regarded as safe) affirmation, no questions letter from the Food and Drug Administration (FDA). D-Ribose® is found also in many energy drinks, bars and supplements.

For more information, contact Renee Cooper of Christie Communications at 805-969-3744 or rcooper@christiecomm.com.

(1)  Gebhart B, Jorgenson JA. Benefit of ribose in a patient with fibromyalgia. Pharmacotherapy. 2004 Nov;24(11):1646-8

(2)  Teitelbaum J, Johnson C, Cyr J. The Use of D-Ribose in Chronic Fatigue Syndrome and Fibromyalgia: A Pilot Study. The Journal of Alternative and Complementary Medicine. 2006 12(9):857-862


'/>"/>
SOURCE Bioenergy Life Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bersin & Associates Introduces New Talent Management Framework
2. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
3. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
4. Ethicon Endo-Surgery Introduces Two New Staplers for Open Surgical Procedures at ASCRS
5. Biosense Webster Introduces the THERMOCOOL(R) SF Irrigated Catheter in the European Union
6. Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access
7. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
8. Burton Medical Introduces the AIM-200(R) as a Versatile, Long-Lasting Light Source for Ambulatory Surgical Centers
9. Sikorsky Global Helicopters Introduces State-of-the-Art Emergency Medical Services Interior for S-76(R) Helicopter
10. Samplify Introduces New Compression Technology to Lower Costs for Mobile Operators Migrating to 4G
11. Bayer Diabetes Care Introduces DIDGET In the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain company ... Tina Howe joined the team, the Bill Howe brand was born and they began ... and giving back to the San Diego community in which they worked, lived and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
Breaking Medicine News(10 mins):